Logo

American Heart Association

  2
  0


Final ID: MDP303

High Frequency of Ejection Fraction Decline in Patients with Heart Failure with Improved Ejection Fraction

Abstract Body (Do not enter title and authors here): Background: Heart failure with improved ejection fraction (HFimpEF) is defined by prior HF with reduced EF (HFrEF) and evidence of systolic improvement and is associated with improved outcomes. Despite this, HFimpEF patients remain at risk of future adverse events, including EF decline. However, little is known about factors associated with EF trajectory in this population.
Question: Are baseline clinical characteristics associated with future EF decline in HFimpEF?
Goals: To describe the EF trajectory in HFimpEF and to identify if clinical characteristics are predictive of eventual EF decline.
Methods: This was a retrospective observational study of 115 patients in our HFimpEF registry. Inclusion criteria were a history of HFimpEF (prior HFrEF [EF ≤40%] with subsequent EF improvement ≥10% and resulting EF >40%) and at least one follow-up echocardiogram after improvement. The primary outcome was EF decline (EF drop ≥10% from peak improvement EF). Cox proportional hazard models were built using baseline factors at time of HFrEF diagnosis to identify predictors of EF decline.
Results: The median time from initial HFrEF diagnosis to development of HFimpEF was 0.61 years (IQR 0.26-1.17). Most patients (77%) continued to have EF improvement after HFimpEF diagnosis, and the peak EF was 60% (IQR 54-65%). Over a mean follow-up of 4.7±3.2 years, 35 (30%) HFimpEF patients developed EF decline. Baseline characteristics were similar between those with sustained EF and EF decline (Table 1), as was peak EF (60.0% vs 60.3%, p=0.571). Indexed end-systolic dimension (1.78 vs 1.93 cm/m2, p=0.014) was smaller at time of HFimpEF diagnosis in those with sustained EF. In multivariate analysis, current/former tobacco use was associated with EF decline (HR 2.60, 95% CI 1.02-6.63, p=0.045; Table 2).
Conclusions: Many HFimpEF patients develop EF decline, highlighting the need for continual clinical follow up in this high-risk patient population.
  • Pensa, Anthony  ( Northwestern University , Chicago , Illinois , United States )
  • Davis, Lucia  ( Northwestern University , Chicago , Illinois , United States )
  • Wu, Tingqing  ( Northwestern University , Chicago , Illinois , United States )
  • Zheng, Veronica  ( Northwestern University , Chicago , Illinois , United States )
  • Harap, Rebecca  ( Northwestern University , Chicago , Illinois , United States )
  • Wilcox, Jane  ( Northwestern University , Chicago , Illinois , United States )
  • Author Disclosures:
    Anthony Pensa: DO NOT have relevant financial relationships | Lucia Davis: DO NOT have relevant financial relationships | Tingqing Wu: No Answer | Veronica Zheng: DO NOT have relevant financial relationships | Rebecca Harap: No Answer | Jane Wilcox: DO have relevant financial relationships ; Advisor:Abiomed:Active (exists now) ; Consultant:Astra Zeneca:Past (completed) ; Speaker:Boehringer Ingelheim:Active (exists now) ; Consultant:Abbott:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Hot Topics in Heart Failure Research

Saturday, 11/16/2024 , 11:10AM - 12:35PM

Moderated Digital Poster Session

More abstracts on this topic:
More abstracts from these authors:
Discussant: SUMMIT CMR

Kramer Chris, Rider Oliver, Wilcox Jane

Lost to Follow Up: A Rare Case of Malonyl-CoA Decarboxylase Deficiency Induced Cardiomyopathy in an Adult Spanish Speaking Hispanic Male

Iniguez Reniell, Quaggin-smith Jessica, Hale Sarah, Wilcox Jane

You have to be authorized to contact abstract author. Please, Login
Not Available